Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lukas BiomedicalROCO:6814 +0.20%66 Days Inventory is 196.34 as of Dec. 2025, which is 41% above its 10-year median of 138.81. GuruFocus rates ROCO:6814 with a GF Score™ of 66/100 and a GF Value™ of NT$21.77 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 638 Biotechnology companies, Lukas Biomedical ranks worse than 53.29% on this metric.
The historical rank and industry rank for Lukas Biomedical's Days Inventory or its related term are showing as below:
ROCO:6814'
s Days Inventory Range Over the Past 10 Years
Min: 54.17 Med: 138.81 Max: 194.12
Current: 194.12
During the past 8 years, Lukas Biomedical's highest Days Inventory was 194.12. The lowest was 54.17. And the median was 138.81.
ROCO:6814's Days Inventory is ranked worse than 53.29% of 638
companies
in the Biotechnology industry
Industry Median: 183.195
vs ROCO:6814: 194.12
Lukas Biomedical's Days Inventory
increased
from Dec. 2024 (178.28) to Dec. 2025 (196.34).
It might indicate that Lukas Biomedical's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Lukas Biomedical's Inventory Turnover for the
six
months ended in Dec. 2025 was 0.93.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Lukas Biomedical's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.42.
Lukas Biomedical (ROCO:6814) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Lukas Biomedical's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Lukas Biomedical's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Lukas Biomedical Days Inventory Related Terms
Lukas Biomedical Days Inventory Historical Data
* Premium members only.
The historical data trend for Lukas Biomedical's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6814 vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Lukas Biomedical's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lukas Biomedical Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lukas Biomedical's Days Inventory distribution charts can be found below:
* The bar in red indicates where Lukas Biomedical's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lukas Biomedical (ROCO:6814) has a Days Inventory of 196.34 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Lukas Biomedical and its competitors. This is 41% above median its historical median of 138.81. Over the past decade, Lukas Biomedical's Days Inventory has ranged from 54.17 to 194.12. According to the industry distribution chart, Lukas Biomedical ranks #340 out of 638 companies in the Biotechnology industry, placing it in the top 53.3%.
Is Lukas Biomedical's Days Inventory too high?
Lukas Biomedical's current Days Inventory of 196.34 is 41% above median its 10-year median of 138.81. Over the past 10 years, this metric has ranged from a low of 54.17 to a high of 194.12. The Biotechnology industry median Days Inventory is 183.20. Lukas Biomedical's value of 196.34 is 7.2% above this industry median. Based on the distribution chart, Lukas Biomedical ranks #340 out of 638 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Lukas Biomedical has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lukas Biomedical's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lukas Biomedical ranks #340 out of 638 companies for Days Inventory. This places Lukas Biomedical in the lower half of its industry. The industry median Days Inventory is 183.20. Lukas Biomedical's value of 196.34 is 7.2% above this benchmark. Historically, Lukas Biomedical's own Days Inventory has ranged from 54.17 to 194.12 over the past decade. While the company's 10-year median is 138.81 vs. the industry median of 183.20, Lukas Biomedical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lukas Biomedical's current Days Inventory of 196.34 is 7.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Lukas Biomedical and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lukas Biomedical's current Days Inventory is 196.34, which is 41% above median its own 10-year median of 138.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lukas Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lukas Biomedical (ROCO:6814) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$21.77, compared to a current price of NT$24.70 — trading 13.5% above its estimated fair value. The current Days Inventory is 196.34, which is 41% above median its 10-year median of 138.81 and 7.2% above the Biotechnology industry median of 183.20. Lukas Biomedical's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Lukas Biomedical (ROCO:6814), the current Days Inventory is 196.34 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lukas Biomedical (ROCO:6814) Overvalued in 2026?
Based on GuruFocus' analysis, Lukas Biomedical stock appears to be overvalued.
The current stock price of NT$24.70 is trading 13.5% above its estimated GF Value™ of NT$21.77.
GuruFocus considers Lukas Biomedical to be Modestly Overvalued.
Key valuation signals for ROCO:6814:
Days Inventory: 196.34 (41% above median its 10-year median of 138.81)
GF Value™: NT$21.77 vs. price of NT$24.70 (13.5% above fair value)
Industry Position: 7.2% above the Biotechnology median (#340 of 638)
No single metric tells the full story. See the ROCO:6814 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lukas Biomedical Inc. is engaged in researching and developing immunotherapy for cancer treatment technologies. The company's main business activities include developing immunocellular therapy, leasing and selling medical equipment, and selling biotech beauty products.
66GF Score
Get the complete analysis for ROCO:6814
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6814 has been successfully added to your 
